More clinical research is needed to clarify the potential role in therapy of some interesting nutraceuticals with strong preclinical evidence of efficacy, such as guggulipid (Commiphora mukul) [23] and curcumin (Curcuma longa) [40]. The most convincing evidence suggest that the association of a bowel cholesterol inhibitor nutraceutical and a cholesterol excreting natural molecule (in particular, berberine) to a statin could be an efficient and safe approach to improve cholesterolemia control in a large number of patients.

However, some nutraceuticals could exert a significant reduction in LDL-cholesterol (Table 11.1), thus clinicians should be informed about their efficacy and safety, in order to use them as preventive tools as additive tools to potentiate more conventional treatments in high-risk subjects. They should also be able to give the consumer full information about the product they are assuming. Further clinical research is advisable to individuate between the available lipid-lowering nutraceuticals with the best cost-effectiveness and risk-benefit ratio for large use in the general population, and in particular in statin treated patients.